Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 20 |
| List of Tables | 19 | 2 |
| List of Figures | 21 | 1 |
| Introduction | 22 | 1 |
| Global Markets Direct Report Coverage | 22 | 1 |
| Epilepsy Overview | 23 | 1 |
| Therapeutics Development | 24 | 2 |
| Pipeline Products for Epilepsy Overview | 24 | 1 |
| Pipeline Products for Epilepsy Comparative Analysis | 25 | 1 |
| Epilepsy Therapeutics under Development by Companies | 26 | 7 |
| Epilepsy Therapeutics under Investigation by Universities/Institutes | 33 | 2 |
| Epilepsy Pipeline Products Glance | 35 | 4 |
| Late Stage Products | 35 | 1 |
| Clinical Stage Products | 36 | 1 |
| Early Stage Products | 37 | 1 |
| Unknown Stage Products | 38 | 1 |
| Epilepsy Products under Development by Companies | 39 | 10 |
| Epilepsy Products under Investigation by Universities/Institutes | 49 | 1 |
| Epilepsy Companies Involved in Therapeutics Development | 50 | 65 |
| Adamas Pharmaceuticals, Inc. | 50 | 1 |
| Advicenne | 51 | 1 |
| Aeolus Pharmaceuticals, Inc. | 52 | 1 |
| Aequus Pharmaceuticals Inc. | 53 | 1 |
| Aestus Therapeutics, Inc. | 54 | 1 |
| Alexza Pharmaceuticals, Inc. | 55 | 1 |
| Anavex Life Sciences Corp. | 56 | 1 |
| Asklepios BioPharmaceutical, Inc. | 57 | 1 |
| Astellas Pharma Inc. | 58 | 1 |
| Bial - Portela &Ca, S.A. | 59 | 1 |
| BioCrea GmbH | 60 | 1 |
| Biogen Inc | 61 | 1 |
| Bionomics Limited | 62 | 1 |
| Biovista Inc. | 63 | 1 |
| Biscayne Pharmaceuticals, Inc. | 64 | 1 |
| Catalyst Pharmaceuticals, Inc. | 65 | 1 |
| D-Pharm Ltd. | 66 | 1 |
| Eisai Co., Ltd. | 67 | 1 |
| Glialogix, Inc. | 68 | 1 |
| Grifols, S.A. | 69 | 1 |
| GW Pharmaceuticals Plc | 70 | 1 |
| H. Lundbeck A/S | 71 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 72 | 1 |
| INSYS Therapeutics, Inc. | 73 | 1 |
| INVENT Pharmaceuticals, Inc. | 74 | 1 |
| Iproteos S.L. | 75 | 1 |
| Johnson &Johnson | 76 | 1 |
| Knopp Biosciences LLC | 77 | 1 |
| Lead Discovery Center GmbH | 78 | 1 |
| Lipicard Technologies Limited | 79 | 1 |
| Lotus Pharmaceutical Co., Ltd. | 80 | 1 |
| Marathon Pharmaceuticals, LLC | 81 | 1 |
| Marinus Pharmaceuticals, Inc. | 82 | 1 |
| Mitochon Pharmaceuticals, Inc. | 83 | 1 |
| Neurelis, Inc. | 84 | 1 |
| Neurocrine Biosciences, Inc. | 85 | 1 |
| Neuron Biopharma SA | 86 | 1 |
| Novartis AG | 87 | 1 |
| OPKO Health, Inc. | 88 | 1 |
| Ovid Therapeutics Inc. | 89 | 1 |
| Pfizer Inc. | 90 | 1 |
| PharmatrophiX, Inc. | 91 | 1 |
| Promius Pharma, LLC | 92 | 1 |
| PTC Therapeutics, Inc. | 93 | 1 |
| Retrophin Inc. | 94 | 1 |
| Sage Therapeutics, Inc. | 95 | 1 |
| Saniona AB | 96 | 1 |
| SciFluor Life Sciences, LLC | 97 | 1 |
| Shire Plc | 98 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 99 | 1 |
| Suda Ltd | 100 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 101 | 1 |
| Takeda Pharmaceutical Company Limited | 102 | 1 |
| Trillium Therapeutics Inc. | 103 | 1 |
| Turing Pharmaceuticals AG | 104 | 1 |
| UCB S.A. | 105 | 1 |
| Ultragenyx Pharmaceutical Inc. | 106 | 1 |
| Upsher-Smith Laboratories, Inc. | 107 | 1 |
| Vichem Chemie Research Ltd. | 108 | 1 |
| VistaGen Therapeutics , Inc. | 109 | 1 |
| Vitality Biopharma Inc | 110 | 1 |
| Xenon Pharmaceuticals Inc. | 111 | 1 |
| XERIS Pharmaceuticals, Inc. | 112 | 1 |
| Zogenix, Inc. | 113 | 1 |
| Zynerba Pharmaceuticals, Inc. | 114 | 1 |
| Epilepsy Therapeutics Assessment | 115 | 18 |
| Assessment by Monotherapy Products | 115 | 1 |
| Assessment by Target | 116 | 6 |
| Assessment by Mechanism of Action | 122 | 7 |
| Assessment by Route of Administration | 129 | 2 |
| Assessment by Molecule Type | 131 | 2 |
| Drug Profiles | 133 | 262 |
| 2-DG Drug Profile | 133 | 2 |
| ADS-4101 Drug Profile | 135 | 1 |
| ADS-9000 Drug Profile | 136 | 1 |
| ADV-6208 Drug Profile | 137 | 1 |
| ADV-6770 Drug Profile | 138 | 1 |
| AEOL-11114 Drug Profile | 139 | 1 |
| AEOL-11203 Drug Profile | 140 | 1 |
| AEOL-11207 Drug Profile | 141 | 2 |
| alprazolam Drug Profile | 143 | 2 |
| AMPX-0079 Drug Profile | 145 | 1 |
| ANAVEX-273 Drug Profile | 146 | 9 |
| ataluren Drug Profile | 155 | 9 |
| AUC-012 Drug Profile | 164 | 1 |
| AV-101 Drug Profile | 165 | 3 |
| AVL-5189 Drug Profile | 168 | 1 |
| BIS-001 Drug Profile | 169 | 2 |
| BNP-TLE Drug Profile | 171 | 1 |
| BPS-015 SR Drug Profile | 172 | 1 |
| brivaracetam Drug Profile | 173 | 4 |
| BVA-601 Drug Profile | 177 | 1 |
| cannabidiol Drug Profile | 178 | 6 |
| cannabidiol Drug Profile | 184 | 3 |
| carbamazepine Drug Profile | 187 | 2 |
| CCG-63802 Drug Profile | 189 | 1 |
| Cell Therapy for Central Nervous System Disorders Drug Profile | 190 | 1 |
| CHEC-9 Drug Profile | 191 | 1 |
| clobazam Drug Profile | 192 | 1 |
| clobazam Drug Profile | 193 | 1 |
| CNV-1061436 Drug Profile | 194 | 1 |
| cosyntropin Drug Profile | 195 | 1 |
| cosyntropin ER Drug Profile | 196 | 1 |
| CPP-115 Drug Profile | 197 | 4 |
| CUR-1916 Drug Profile | 201 | 1 |
| diazepam Drug Profile | 202 | 2 |
| diazepam Drug Profile | 204 | 1 |
| DP-VPA Drug Profile | 205 | 2 |
| Drug for Epilepsy Drug Profile | 207 | 1 |
| Drug for Epilepsy Drug Profile | 208 | 1 |
| Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders Drug Profile | 209 | 1 |
| eslicarbazepine acetate Drug Profile | 210 | 7 |
| everolimus Drug Profile | 217 | 12 |
| fenfluramine hydrochloride Drug Profile | 229 | 3 |
| fosphenytoin sodium Drug Profile | 232 | 1 |
| gaboxadol Drug Profile | 233 | 2 |
| ganaxolone Drug Profile | 235 | 5 |
| Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy Drug Profile | 240 | 1 |
| GLX-1112 Drug Profile | 241 | 1 |
| GWP-42006 Drug Profile | 242 | 2 |
| histamine dihydrochloride Drug Profile | 244 | 1 |
| immune globulin (human) Drug Profile | 245 | 2 |
| INV-107 Drug Profile | 247 | 1 |
| IPR-131 Drug Profile | 248 | 1 |
| IPR-96 Drug Profile | 249 | 1 |
| IPRO-003 Drug Profile | 250 | 1 |
| JNJ-40411813 Drug Profile | 251 | 3 |
| KM-113 Drug Profile | 254 | 1 |
| KM-314 Drug Profile | 255 | 1 |
| lacosamide Drug Profile | 256 | 9 |
| lamotrigine Drug Profile | 265 | 1 |
| LAU-09021 Drug Profile | 266 | 1 |
| levetiracetam Drug Profile | 267 | 3 |
| levetiracetam ER Drug Profile | 270 | 1 |
| LM-22A4 Drug Profile | 271 | 2 |
| lorazepam Drug Profile | 273 | 1 |
| LSPGR-1 Drug Profile | 274 | 1 |
| LT-4121 Drug Profile | 275 | 1 |
| LT-4122 Drug Profile | 276 | 1 |
| LT-4123 Drug Profile | 277 | 1 |
| LT-4124 Drug Profile | 278 | 1 |
| LT-4125 Drug Profile | 279 | 1 |
| LT-4126 Drug Profile | 280 | 1 |
| magnesium valproate hydrate Drug Profile | 281 | 1 |
| MB-003 Drug Profile | 282 | 1 |
| midazolam hydrochloride Drug Profile | 283 | 3 |
| midazolam hydrochloride Drug Profile | 286 | 1 |
| midazolam hydrochloride Drug Profile | 287 | 1 |
| midazolam hydrochloride Drug Profile | 288 | 1 |
| MP-101 Drug Profile | 289 | 1 |
| MRS-5474 Drug Profile | 290 | 1 |
| naluzotan hydrochloride Drug Profile | 291 | 1 |
| NGT-168 Drug Profile | 292 | 1 |
| NH-34 Drug Profile | 293 | 1 |
| NRP-2945 Drug Profile | 294 | 2 |
| NST-0037 Drug Profile | 296 | 1 |
| NST-0076 Drug Profile | 297 | 1 |
| Oligonucleotide for Dravet Syndrome Drug Profile | 298 | 1 |
| perampanel Drug Profile | 299 | 7 |
| PF-06372865 Drug Profile | 306 | 1 |
| pregabalin Drug Profile | 307 | 4 |
| propofol hemisuccinate Drug Profile | 311 | 1 |
| radiprodil Drug Profile | 312 | 2 |
| SAGE-105 Drug Profile | 314 | 1 |
| SAGE-217 Drug Profile | 315 | 2 |
| SAGE-324 Drug Profile | 317 | 1 |
| SAGE-689 Drug Profile | 318 | 1 |
| SCT-66 Drug Profile | 319 | 1 |
| selurampanel Drug Profile | 320 | 2 |
| sepranolone Drug Profile | 322 | 7 |
| SF-0034 Drug Profile | 329 | 2 |
| SGE-872 Drug Profile | 331 | 1 |
| Small Molecule 1 for Epilepsy Drug Profile | 332 | 1 |
| Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 333 | 1 |
| Small Molecule 2 for Epilepsy Drug Profile | 334 | 1 |
| Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 335 | 1 |
| Small Molecule 3 for Epilepsy Drug Profile | 336 | 1 |
| Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy Drug Profile | 337 | 1 |
| Small Molecule 4 for Epilepsy Drug Profile | 338 | 1 |
| Small Molecule for Epilepsy Drug Profile | 339 | 1 |
| Small Molecule for Epilepsy Drug Profile | 340 | 1 |
| Small Molecule for Epilepsy Drug Profile | 341 | 1 |
| Small Molecule for Status Epilepticus Drug Profile | 342 | 1 |
| Small Molecule for Stroke and Epilepsy Drug Profile | 343 | 1 |
| Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain Drug Profile | 344 | 1 |
| Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile | 345 | 1 |
| Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy Drug Profile | 346 | 1 |
| Small Molecule to Block Nav1.6 for Dravet Syndrome Drug Profile | 347 | 1 |
| Small Molecule to Block TRPC4 and TRPC5 for Cardiovascular Disease and Epilepsy Drug Profile | 348 | 1 |
| Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus Drug Profile | 349 | 1 |
| Small Molecules 1 for Epilepsy Drug Profile | 350 | 1 |
| Small Molecules 2 for Epilepsy Drug Profile | 351 | 1 |
| Small Molecules 3 for Epilepsy Drug Profile | 352 | 1 |
| Small Molecules 4 for Epilepsy Drug Profile | 353 | 1 |
| Small Molecules for Epilepsy Drug Profile | 354 | 1 |
| Small Molecules for Seizure Disorders Drug Profile | 355 | 1 |
| Small Molecules for Seizures Drug Profile | 356 | 1 |
| Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS Drug Profile | 357 | 1 |
| Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus Drug Profile | 358 | 1 |
| Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders Drug Profile | 359 | 1 |
| Small Molecules to Agonize GABA-A Receptor For Epilepsy Drug Profile | 360 | 1 |
| Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism Drug Profile | 361 | 1 |
| Small Molecules to Antagonize GPCR for Central Nervous System Diseases Drug Profile | 362 | 1 |
| Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile | 363 | 1 |
| Small Molecules to Inhibit Dynamin for Epilepsy and Oncology Drug Profile | 364 | 1 |
| Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome Drug Profile | 365 | 1 |
| Small Molecules to Target Ion Channels for CNS Disorders Drug Profile | 366 | 1 |
| sulthiame Drug Profile | 367 | 1 |
| TAK-935 Drug Profile | 368 | 1 |
| TF-0081 Drug Profile | 369 | 1 |
| TG-4155 Drug Profile | 370 | 1 |
| topiramate Drug Profile | 371 | 1 |
| TRP-001 Drug Profile | 372 | 1 |
| TUR-004 Drug Profile | 373 | 1 |
| TUR-005 Drug Profile | 374 | 1 |
| UCB-0942 Drug Profile | 375 | 1 |
| UX-007 Drug Profile | 376 | 5 |
| VAD-1 Drug Profile | 381 | 1 |
| VAD-2 Drug Profile | 382 | 1 |
| VAL-0417 Drug Profile | 383 | 1 |
| VB-3323 Drug Profile | 384 | 1 |
| VID-45110 Drug Profile | 385 | 1 |
| VU-0456810 Drug Profile | 386 | 1 |
| YKP-3089 Drug Profile | 387 | 2 |
| Z-944 Drug Profile | 389 | 3 |
| ZYN-002 Drug Profile | 392 | 3 |
| Epilepsy Dormant Projects | 395 | 10 |
| Epilepsy Discontinued Products | 405 | 2 |
| Epilepsy Product Development Milestones | 407 | 13 |
| Featured News &Press Releases | 407 | 1 |
| Aug 14, 2016: U.S. District Court confirms validity of patent for UCB Vimpat | 407 | 1 |